Quote this publication Share Print

EYLEA

-
Opinions on drugs - Posted on Nov 22 2013

Reason for request

Inclusion

-


Clinical Benefit

Substantial

Substantial actual benefit


Clinical Added Value

no clinical added value

EYLEA 40 mg/ml, solution for injection in a prefilled syringe and solution for injection in a vial, does not provide an improvement in actual benefit (IAB V) compared with LUCENTIS 10 mg/ml, solution for injection.


Contact Us

Évaluation des médicaments

See also

All our publications